TipRanks
Advertisement
Advertisement
Actinium Pharmaceuticals: Emerging Pan-Tumor Potential of ATNM-400 Supports Buy Rating and Unchanged $4 Price Target
PremiumRatingsActinium Pharmaceuticals: Emerging Pan-Tumor Potential of ATNM-400 Supports Buy Rating and Unchanged $4 Price Target
4M ago
Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer
Premium
The Fly
Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer
4M ago
Actinium Pharmaceuticals presents new radiochemistry data at SNMMI
Premium
The Fly
Actinium Pharmaceuticals presents new radiochemistry data at SNMMI
4M ago
Actinium presents data from Actimab-A studies at AACR
PremiumThe FlyActinium presents data from Actimab-A studies at AACR
6M ago
Actinium presents preclinical results for ATNM-400 at AACR
Premium
The Fly
Actinium presents preclinical results for ATNM-400 at AACR
6M ago
Actinium Pharmaceuticals: Undervalued Radiopharmaceutical Play with Promising ATNM-400 Pipeline and Near‑Term Catalysts
Premium
Ratings
Actinium Pharmaceuticals: Undervalued Radiopharmaceutical Play with Promising ATNM-400 Pipeline and Near‑Term Catalysts
6M ago
Actinium Pharmaceuticals presents new data on anti-tumor activity of ATNM-400
PremiumThe FlyActinium Pharmaceuticals presents new data on anti-tumor activity of ATNM-400
10M ago
Actinium Pharmaceuticals announces preclinical data for ATNM-400
Premium
The Fly
Actinium Pharmaceuticals announces preclinical data for ATNM-400
11M ago
Actinium Pharmaceuticals Holds Annual Stockholders Meeting
Premium
Company Announcements
Actinium Pharmaceuticals Holds Annual Stockholders Meeting
11M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―